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Abstract
Background: Septic cardiomyopathy (SCM) is common in sepsis and associated with
increased morbidity and mortality. Left ventricular global longitudinal strain (LV GLS),
measured by speckle tracking echocardiography, allows improved identification of
impaired cardiac contractility. The peripheral blood transcriptome may be an
important window into SCM pathophysiology. We therefore studied the peripheral
blood transcriptome and LV GLS in a prospective cohort of patients with sepsis.
Results: In this single-center observational pilot study, we enrolled adult patients (age
> 18) with sepsis within 48 h of admission to the ICU. SCM was defined as LV GLS > −
17% based on echocardiograms performed within 72 h of admission. We enrolled 27
patients, 24 of whom had high-quality RNA results; 18 (75%) of 24 had SCM. The group
was 50% female and had a median (IQR) age of 59.5 (48.5–67.0) years and admission
APACHE II score of 21.0 (16.0–32.3). Forty-six percent had septic shock. After filtering for
low-expression and non-coding genes, 15,418 protein coding genes were expressed
and 73 had significantly different expression between patients with vs. without SCM. In
patients with SCM, 43 genes were upregulated and 30 were downregulated. Pathway
analysis identified enrichment in type 1 interferon signaling (adjusted p < 10−5).
Conclusions: In this hypothesis-generating study, SCM was associated with
upregulation of genes in the type 1 interferon signaling pathway. Interferons are
cytokines that stimulate the innate and adaptive immune response and are implicated
in the early proinflammatory and delayed immunosuppression phases of sepsis. While
type 1 interferons have not been implicated previously in SCM, interferon therapy (for
viral hepatitis and Kaposi sarcoma) has been associated with reversible cardiomyopathy,
perhaps suggesting a role for interferon signaling in SCM.
Keywords: Global longitudinal strain, Interferon, Sepsis
Background
Current consensus defines sepsis as life-threatening organ dysfunction in the setting of
an abnormal host response to infection. Cardiac dysfunction in sepsis, i.e., “septic car-
diomyopathy (SCM),” is common and if severe, may contribute to the dysfunction of
other organs in the septic patient [1]. Left ventricular global longitudinal strain (LV
GLS) has been identified as an accurate, non-invasive measure of cardiac contractility,
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium,
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and
indicate if changes were made.
Intensive Care Medicine
Experimental
Cirulis et al. Intensive Care Medicine Experimental            (2019) 7:57 
https://doi.org/10.1186/s40635-019-0271-0
allowing improved interrogation of the pathophysiology of SCM [2–7]. Compared
to the traditional measurement of LV ejection fraction (EF), LV GLS is less
dependent on cardiac preload and afterload—conditions that can change often and
rapidly during the course of sepsis and septic shock [3, 4]. Mechanistically, numer-
ous factors related to the dysregulated inflammatory response have been hypothe-
sized to play a role in the development of SCM, although none are confirmed to
be causative [8–10].
Peripheral blood transcriptome analysis enables exploration of gene expression
profiles in disease states of interest. No study has examined the peripheral blood
transcriptome in patients with SCM. In this pilot study, we compared the periph-
eral blood transcriptional profile of septic patients with and without SCM as de-
fined by LV GLS.
Methods
Study design and patient data
We report a sub-study of a larger prospective single-center observational study of post-
sepsis cognitive impairment (NCT03015584) (Fig. 1). Full parent study eligibility cri-
teria are reported on the ClinicalTrials.gov website; briefly, we enrolled patients with
sepsis (SEPSIS-3 criteria) admitted to a study ICU from June 2015 to July 2017. Patients
had to be enrolled within 48 h of admission to the study ICU and were excluded for
the following: onset of sepsis or septic shock > 24 h after hospital admission or transfer
to the ICU was > 48 h after admission (with admitting diagnosis of sepsis); transfer
from another hospital except directly from emergency room; prior prespecified neuro-
logic or psychiatric comorbidities or cardiac surgery; “Do Not Resuscitate/Do not
Intubate” order prior to study enrollment; known pregnancy; primary diagnosis of drug
overdose; or attending physician deemed aggressive care unsuitable or the patient was
not expected to survive 48 h. Patients with a clinical echocardiogram within the first 72
h of admission were included in this sub-study. We collected blood for whole blood
Fig. 1 Consort diagram illustrating patient selection for parent and sub-study
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RNA sequencing at time of enrollment. We also gathered patient demographics and se-
verity of illness parameters.
Laboratory analysis
RNA sequencing was performed on blood drawn at the time of enrollment using estab-
lished methods (Illumina platform). Blood was drawn in PAXgene tubes and immediately
frozen at − 20 °C. We extracted RNA from peripheral whole blood using PAXgene Blood
RNA Kit IVD (Qiagen Cat #762164), with ~ 1mcg of RNA isolated from whole blood.
One hundred nanograms of this RNA was used for Next Generation RNA sequencing
(using the Illumina kits with Ribo-Zero Globin processing, 50 cycle single read), aligned to
H_sapiens_Feb_2009_B37. Total RNA samples (100–500 ng) were hybridized with Ribo-
Zero Globin to substantially deplete both globin RNA and rRNA species from the sam-
ples. Stranded RNA sequencing libraries were prepared as described using the Illumina
TruSeq Stranded Total RNA Kit with Ribo-Zero Globin (RS-122-2501 and RS-122-2502).
Purified libraries were qualified on an Agilent Technologies 2200 TapeStation using a
D1000 ScreenTape assay (cat# 5067-5582 and 5067-5583). The molarity of adapter-
modified molecules was defined by quantitative PCR using the Kapa Biosystems Kapa
Library Quant Kit (cat#KK4824). Individual libraries were normalized to 10 nM, and equal
volumes were pooled in preparation for Illumina sequence analysis. Sequencing libraries
(25 pM) were chemically denatured and applied to an Illumina HiSeq v4 single-read flow
cell using an Illumina cBot. Hybridized molecules were clonally amplified and annealed to
sequencing primers with reagents from an Illumina HiSeq SR Cluster Kit v4-cBot (GD-
401-4001). Following transfer of the flowcell to an Illumina HiSeq 2500 instrument
(HCSv2.2.38 and RTA v1.18.61), a 50-cycle single-read sequence run was performed using
HiSeq SBS Kit v4 sequencing reagents (FC-401-4002).
The human GRCh38 FASTA and gene transfer format (GTF) files were downloaded
from Ensembl release 87, and the reference database was created using STAR version
2.5.2b [11] with splice junctions optimized for 50 base pair reads. Reads were trimmed
of adapters and aligned to the reference database using STAR in two-pass mode to out-
put a Binary Alignment Map (BAM) file sorted by coordinates. Mapped reads were
assigned to annotated genes in the GTF file using featureCounts version 1.5.1 [12]. The
output files from FastQC, Picard CollectRnaSeqMetrics, STAR, and featureCounts were
summarized using MultiQC [13] to check for any sample outliers.
Statistical analysis
Differentially expressed genes were identified using a 10% false discovery rate (FDR) with
DESeq2 version 1.18 [14]. All the expressed genes were sorted by log2 fold change and com-
pared to Reactome pathways using gene set enrichment analysis (GSEA) [15]. In addition,
significant genes were compared to the same pathways using Fisher’s exact test to find sig-
nificant overlaps. We performed analyses in R version 3.2.3 (Vienna, Austria) [16].
Echocardiography
We used clinically acquired two-dimensional echocardiograms obtained within 72 h of
admission performed at the discretion of the treating physician. In the study ICU, clin-
ical echocardiograms are routinely obtained for the management of patients with
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serious sepsis and septic shock. We retrospectively measured LV GLS following a
standard protocol on apical four-chamber views using the Image-Arena platform
(Tomtec Imaging Systems, Unterschleissheim, Germany) as we have applied in other
cohorts [3]. We used the best single cardiac cycle and rejected images if we could not
perform tracking on two or more adjacent segments. We defined abnormal strain as
greater than − 17%, consistent with prior work in patients with septic shock [17, 18].
Results
Patient characteristics
A total of 631 patients were screened for the parent study, 40 of whom were enrolled.
Of those 40 patients, 27 patients had an echocardiogram performed in the first 72 h
and 24 had RNA results of sufficient quality for interpretation (Fig. 1). Median time to
first echocardiogram was 1.3 h (IQR 0.3–3.8) from ICU admission; median time be-
tween RNA sample collection and echocardiogram was 14.5 h (IQR 10.7–21.4). Charac-
teristics of the cohort are listed in Table 1, including source of sepsis when available.
Eighteen of the 24 patients (75%) met LV GLS criteria for SCM. Overall, the group was
50% female and had a median (IQR) age of 59.5 years (48.5–67.0) and admission APA-
CHE II score of 21.0 (16.0–32.3). Forty-six percent of the cohort met the SEPSIS-3 cri-
teria for septic shock; a similar rate of septic shock was seen between those with and
without SCM (44% vs. 50%). Median LV ejection fraction was 57% in the SCM group
and 66% in patients without SCM. Those with SCM had more comorbid medical con-
ditions than those without (median Elixhauser Comorbidity Index 17.0 vs. 9.5). ICU
length of stay was 3.7 days vs. 2.9 days in those with vs. those without SCM, and mor-
tality was 22% vs. 0% in the two groups. Source of infection was identified in 94% of
those with SCM and 67% of those without; pneumonia was the most frequent type of
infection in the patients with SCM (39%). The rate of infection with gram-positive and
gram-negative organisms was similar between the two groups. Only two patients were
identified to have a viral infection (one isolated, one concurrent with a bacterial infec-
tion), both of which were in the SCM group.
Transcriptional profiling
After filtering for low-expression and non-coding genes, 15,418 protein coding genes
were identified, and 73 had significantly different expression between patients with vs.
without SCM. In the patients with SCM, 43 genes were upregulated and 30 were down-
regulated, as shown in the volcano plot (Fig. 2a). Unsupervised hierarchical clustering
of the differentially expressed mRNA demonstrates the patterns of expression within
the SCM and non-SCM groups displayed in Fig. 2b.
Pathway analysis using GSEA identified significant enrichment in several pathways;
the most enriched pathways (positive or negative) are displayed in Table 2. Notably, we
observed positive enrichment in interferon (IFN) signaling (adjusted p < 0.005) in pa-
tients with SCM; the top pathway in terms of differential expression was type 1 IFN
signaling.
Similarly, type 1 IFN signaling was also the top pathway in overrepresentation
pathway analysis (p < 10−7). Figure 3 demonstrates the gene ontology category overrep-
resentation for genes dysregulated in patients with SCM. The most significantly
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overrepresented categories were those related to viral response to infection and type 1
IFN signaling. We attempted an exploration of the relationship between infecting
microorganism and the transcriptome, but the small number of individuals in each
group and the presence of polymicrobial infection in a substantial proportion prevented
a successful analysis.
Discussion
In this exploratory pilot study, SCM (as defined by LV GLS of > − 17%) was associated
with upregulation of genes in IFN signaling pathways, including type 1 IFN and IFN
Table 1 Characteristics of patients with and without septic cardiomyopathy
Septic cardiomyopathy
(n = 18)
No septic
cardiomyopathy
(n = 6)
Age (years); median (IQR) 62.0 (43.8–67.0) 57 (54.0–64.5)
Admission APACHE II (points); median (IQR) 18.5 (14.5–36.0) 22.5 (20.5–23.0)
Female, n (%) 7 (39%) 5 (83%)
Septic shock, n (%) 8 (44%) 3 (50%)
Elixhauser comorbidity score (points);
median (IQR)
17 (6.8–26.0) 9.5 (4.3–11.8)
Mechanically ventilated, n (%) 7 (39%) 1 (17%)
Duration of mechanical ventilation
among those ventilated (days); median (IQR)
1.7 (0.8–2.4) 2.8a
ICU length of stay; median (IQR) 3.7 (2.5–4.7) 2.9 (2.5–3.3)
Hospital length of stay; median (IQR) 8.0 (5.0–13.6) 5.6 (5.1–6.0)
90-day mortality 4 (22%) 0 (0%)
Echocardiogram data
Median (IQR)
LV GLS − 11.4 (− 13.6 to − 8.4) −19.8 (− 21.0 to − 17.3)
LV ejection fraction % 57 (45–66) 66 (64–68)
Source of infection, n (%)
Pneumonia 7 (39%) 1 (17%)
Urinary tract infection 3 (17%) 1 (17%)
Skin and soft tissue 4 (22%) 1 (17%)
Intra-abdominal 2 (11%) 1 (17%)
CLABSI 1 (6%) 0 (0%)
Unknown 1 (6%) 2 (33%)
Bacteremia present 7 (39%) 2 (33%)
Organism type, n (%)
Bacterial 13 (72%) 3 (50%)
Viral 1 (6%) 0
Mixedb 1 (6%) 0
Unknown 3 (17%) 3 (50%)
Microbiologyc, n (%)
Gram positive 10 (55%) 3 (50%)
Gram negative 6 (33%) 2 (33%)
LV left venticular, CLABSI central line-associated bloodstream infection
aOnly one patient mechanically ventilated and duration was 2.8 days
bBacterial and viral infection
cSome subjects had polymicrobial infection (gram positive and gram negative)
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gamma. Repressed pathways include those important for RNA polymerase function and
telomere maintenance and packaging. Type 1 IFN signaling was the top pathway in
both GSEA and overrepresentation pathway analysis.
Type 1 IFNs (especially α and β) are widely expressed and signal through a specific
receptor (IFNAR) to induce changes in the expression of hundreds of downstream
genes [19]. Ligation of intracellular (viral) or cell surface (bacterial) pattern recognition
receptors (PRR) leads to activation of nuclear transcription factors that drive expression
of type 1 IFNs [19]. Type 1 IFN signaling was initially recognized for antiviral proper-
ties, but studies in recent decades have identified the pleotropic effects of type 1 IFN
signaling in a variety of bacterial infections as well [19]. IFN α and β have been studied
in sepsis, mostly in gram-negative endotoxemia, and are implicated in both the early
proinflammatory and delayed immunosuppressive phases [20].
Although IFN signaling has not been directly implicated in prior investigations of the
pathogenesis of SCM, there is substantial overlap between factors associated with car-
diac dysfunction in sepsis and the canonical IFN pathway. For instance, activation of
toll-like receptor 4 (TLR4) by lipopolysaccharide (LPS) in gram-negative infection sig-
nals through intracellular TIR-domain-containing adaptor-inducing beta interferon
(TRIF) to increase expression of IFN-β. TLR4 activation also signals through MyD88 to
Table 2 Top pathways in gene sequence enrichment analysis (GSEA)
Top pathways in gene sequence
enrichment analysis (GSEA)
Normalized enrichment
score
Direction of
enrichment
Type 1 interferon signaling 2.96 ↑
Interferon signaling 2.68 ↑
Peptide chain elongation 2.51 ↑
Interferon gamma signaling 2.42 ↑
RNA Pol I promoter opening − 2.80 ↓
Telomere maintenance − 2.70 ↓
Packaging of telomere ends − 2.66 ↓
RNA Pol I transcription − 2.65 ↓
Adjusted p < 0.05 for all pathways
Fig. 2 RNAseq analysis of patients with septic cardiomyopathy compared to those without SCM
demonstrates differential gene expression. a Volcano plot illustrating fold differences in gene expression in
septic cardiomyopathy vs. non-septic cardiomyopathy subjects. b Heatmap of differentially expressed
mRNAs using unsupervised hierarchical clustering. SCM, septic cardiomyopathy
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activate the NFκB transcription factor which increases expression of classic inflamma-
tory cytokines IL-1 and TNFα [20]. There is significant cross talk between TNFα/IL-1
and type 1 IFN signaling pathways, mostly in a counterregulatory fashion, but TNFα
has also been shown to stimulate production of IFN-β in an autocrine signaling loop
[21–23]. TLR4, IL-1, and TNFα have all been hypothesized to play a role in the devel-
opment of SCM [24–27]. Additionally, acting through the STAT transcription factor,
IFN-β increases expression of inducible nitric oxide synthase (iNOS) and thus nitric
oxide (NO) production. IFN gamma may also interact with LPS in gram-negative sepsis
to induce NOS activity [28]. It has recently been suggested that endothelial NO over-
production may lead to both early and late cardiac dysfunction in sepsis [29–31].
Adding to the biologic plausibility that type 1 IFN signaling may play a role in the de-
velopment of SCM is the historical experience with IFN chemotherapy in select cancers
(e.g., Kaposi sarcoma) and viral hepatitis. A review of 44 patients with interferon-
related cardiotoxicity identified five cases of frank cardiomyopathy. Other reported ef-
fects included arrhythmia, myocardial ischemia, and sudden death. In the majority of
cases, IFN-associated cardiac dysfunction reversed with drug discontinuation [32]. Oc-
casionally, IFN-associated cardiac function may be irreversible and lead to death. In
one report, autopsy in such a case revealed drug-induced cardiomyopathy [33]. The
mechanism by which IFN α causes cardiac toxicity is currently unknown.
Our study has several limitations. First, sample size was small, and most patients had
SCM, with an imbalance by sex between patients with and without SCM. These distri-
butions, probably by chance, may limit confidence in results, although the imbalance
by sex may also represent sex differences in cardiac function as observed in other dis-
ease states [34]. The causative organism was undetermined in 17% and 50% of subjects
with and without SCM, respectively. Unlike standard testing for bacterial organisms
(i.e., blood cultures), viral screening is not routine and therefore viral infections could
be missed if not clinically suspected and tested for by the treating physician. Viral or-
ganisms are a classic trigger for the type 1 interferon pathway [19], and correlation with
SCM may become apparent if all viral infections could be identified.
Another potential limitation of this study is the threshold of LV GLS chosen to define
SCM. While we used a previously published definition of LV dysfunction (> − 17%) [17,
18], this limit may overestimate the frequency of SCM, as 75% of our study population
met this criterion. The median LVEF in the SCM cohort was 57%, which is still
Fig. 3 Gene ontology category overrepresentation for dysregulated genes in patients with
septic cardiomyopathy
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considered normal by the American Society of Echocardiography guidelines [35]. The
clinical relevance of mild LV dysfunction in the setting of sepsis and septic shock is un-
clear. A second possible explanation for the high prevalence of SCM in this study is
selection bias. Subjects had to have a clinically acquired echocardiogram to be included
in the study population, and treating clinicians at the study ICU are more likely to
order an echocardiogram if a patient is hemodynamically unstable. This tendency may
have led to exclusion of patients with milder forms of sepsis and inclusion of a higher
proportion of patients with septic shock (46% overall), limiting the generalizability of
the findings to a general sepsis cohort.
As is true for most studies of sepsis, patients may have been enrolled at various time
points in the course of their sepsis [36]. Similarly, echocardiograms were performed at
various points in the early phase of the ICU stay. Given that the natural history of SCM
is at present undefined, the chosen time point (early vs. late sepsis) could alter the re-
ported prevalence and the transcriptome results; late SCM may be associated with a
different profile. Lastly, the transcriptomic analysis was not confirmed to correlate with
protein expression of the molecules of interest in analyses of peripheral blood protein/
cytokine levels. Future studies that control for time of sepsis onset and validate with
proteomic analysis will improve the generalizability of transcriptome analyses.
Conclusions
In this exploratory study of sepsis patients, canonical type 1 IFN signaling is upregu-
lated in peripheral leucocytes among patients with SCM compared to those without
SCM. Interferons are previously implicated in sepsis pathophysiology but have not to
our knowledge been reported as a potential contributor to SCM. Multiple lines of evi-
dence suggest possible biological plausibility, but further studies are required to deter-
mine whether IFN may in fact play an etiologic role in SCM.
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